Rivaroxaban's vascular dose for the neurovascular clinician.

Chin Neurosurg J

Neurovascular Fellow, New York Medical College, Westchester Medical Center, Valhalla, NY, USA.

Published: July 2024

Rivaroxaban, a direct oral anticoagulant, has proven efficacy and safety at its standard dose in the treatment and prevention of various vascular conditions. These include the treatment of venous thromboembolism and stroke prevention in non-valvular atrial fibrillation. A "very low" vascular dose of rivaroxaban, when combined with low-dose aspirin, has been demonstrated to reduce major adverse cardiovascular events, including stroke, in both acute and chronic coronary syndrome. The combination of rivaroxaban and low-dose aspirin could potentially offer an additional strategy for stroke prevention in selected non-atrial fibrillation patients who are at a high risk of stroke.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11221019PMC
http://dx.doi.org/10.1186/s41016-024-00373-4DOI Listing

Publication Analysis

Top Keywords

vascular dose
8
stroke prevention
8
low-dose aspirin
8
rivaroxaban's vascular
4
dose neurovascular
4
neurovascular clinician
4
clinician rivaroxaban
4
rivaroxaban direct
4
direct oral
4
oral anticoagulant
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!